Research progress on the molecular mechanisms of imatinib resistance in gastrointest-inal stromal tumors
10.12354/j.issn.1000-8179.2024.20240029
- VernacularTitle:伊马替尼治疗胃肠道间质瘤耐药的相关分子机制研究进展
- Author:
Zhao YAN
1
;
Wang YUHAO
;
Wang JUAN
;
Yang JIANJUN
Author Information
1. 西北大学生命科学学院(西安市 710069);空军军医大学第一附属医院西京消化病医院消化外科,消化系肿瘤整合防治全国重点实验室
- Keywords:
gastrointestinal stromal tumor(GIST);
imatinib;
drug resistance;
molecular mechanism
- From:
Chinese Journal of Clinical Oncology
2024;51(4):197-202
- CountryChina
- Language:Chinese
-
Abstract:
Understanding mechanism of imatinib resistance in gastrointestinal stromal tumors(GIST)and developing new therapeutic tar-gets and schemes to address this resistance exhibit great potential to improve the long-term prognosis of patients with GIST.This review summarizes exiting research into the molecular characteristics of GIST and mechanisms of imatinib resistance acting via non-coding RNA,lysosomes,key protein molecules,fibroblast growth factor-2(FGF-2),and other modulators.Research shows that different drug resistance mechanism networks are closely connected and interrelated.Combining imatinib therapy with multiple drugs that inhibit the resistance mechanism shall present new options treating GIST thereby improving prognosis.Identification and implementation of individualized treat-ment strategies based on drug resistance mechanisms will provide new adjuvant treatment options for patients with GIST resistant to imat-inib,thus delaying progression of GIST.
